.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
India introduced a major oncology breakthrough with the launch of subcutaneous lung cancer immunotherapy. Roche Pharma India recently received CDSCO approval for Tecentriq (atezolizumab) in this new format. Consequently, this innovation promises to transform treatment for metastatic non-small cell lung cancer (NSCLC) patients across the country.
Clinicians administer the new subcutaneous therapy in approximately seven minutes. In contrast, traditional intravenous infusions usually require several hours of hospital time. Therefore, medical teams can significantly optimize their resources. Specifically, hospital chairs can now accommodate up to five patients in the time previously needed for one. However, experts expect the market price to be slightly higher than the existing IV formulation.
Clinical data from global studies confirms that the formulation maintains comparable safety and efficacy to IV delivery. Moreover, healthcare professionals report that the new method simplifies the administration process. Importantly, four out of five patients preferred the subcutaneous route. Patients cited shorter clinic visits and reduced emotional stress as primary reasons for their choice. Additionally, this shift supports the growth of decentralized cancer care in daycare centers.
Q1: How does the new delivery method affect treatment time?
It reduces the administration time from several hours for IV infusion to approximately seven minutes for a subcutaneous injection.
Q2: Has the CDSCO approved this treatment for use in India?
Yes, the CDSCO approved the subcutaneous formulation for eligible adults with adjuvant and metastatic non-small cell lung cancer.
Q3: Is the efficacy of the subcutaneous version different from the IV version?
No, clinical trials such as IMscin001 have demonstrated comparable safety and efficacy profiles between the two formulations.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
India launches Roche's Tecentriq SC, a 7-minute subcutaneous lung cancer immunotherapy that reduces administration time by 80% and enhances patient comfort....
2 months ago
A JAMA study using Global Burden of Disease 2023 data reveals high LDL cholesterol caused 3.6 million deaths globally, with India and China bearing one-third of the disease burden. Addressing systemic barriers to statin therapy and strengthening primary care lipid screening remain critical clinical priorities.
Today
The National Human Rights Commission has directed the Rajasthan government to act on maternal deaths and severe injuries in Kota linked to substandard oxytocin injections. The intervention follows complaints regarding batch quality failures, acute renal injury requiring dialysis, and regulatory oversights.
Today
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
Last week
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
Last week
A comprehensive review highlights major modifiable dementia risk factors in India, emphasizing early-onset diabetes, sensory deficits, undernutrition, and lifestyle interventions to protect cognitive health across diverse populations.
Yesterday
